GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Compumedics Ltd (ASX:CMP) » Definitions » LT-Debt-to-Total-Asset

Compumedics (ASX:CMP) LT-Debt-to-Total-Asset : 0.02 (As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Compumedics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Compumedics's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.02.

Compumedics's long-term debt to total assets ratio declined from Jun. 2023 (0.04) to Jun. 2024 (0.02). It may suggest that Compumedics is progressively becoming less dependent on debt to grow their business.


Compumedics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Compumedics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compumedics LT-Debt-to-Total-Asset Chart

Compumedics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.01 0.04 0.02

Compumedics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.04 0.04 0.03 0.02

Compumedics LT-Debt-to-Total-Asset Calculation

Compumedics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=0.826/40.358
=0.02

Compumedics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0.826/40.358
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compumedics  (ASX:CMP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Compumedics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Compumedics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Compumedics Business Description

Traded in Other Exchanges
N/A
Address
30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing and commercialization of diagnostic technologies for sleep, brain and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of Americas, Australia and the Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.